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Background: Directly observed therapy (DOT), as recommended by the World Health Organization, is used in
many countries to deliver tuberculosis (TB) treatment. The effectiveness of community-based (CB DOT) versus clinic
DOT has not been adequately assessed to date. We compared TB treatment outcomes of CB DOT (delivered by
community health workers or community volunteers), with those achieved through conventional clinic DOT.
Methods: We performed a systematic review and meta-analysis of studies before 9 July 2014 comparing treatment
outcomes of CB DOT and clinic DOT. The primary outcome was treatment success; the secondary outcome was loss
to follow-up.
Results: Eight studies were included comparing CB DOT to clinic DOT, one a randomised controlled trial. CB DOT
outperformed clinic DOT treatment success (pooled odds ratio (OR) of 1.54, 95% confidence interval (CI) 1.01 – 2.36,
p = 0.046, I2 heterogeneity 84%). No statistically significant difference was found between the two DOT modalities
for loss to follow-up (pooled OR 0.86, 95% CI 0.48 to 1.55, p = 0.62, I2 83%).
Conclusions: Based on this systematic review, CB DOT has a higher treatment success compared to clinic DOT.
However, as only one study was a randomised controlled trial, the findings have to be interpreted with caution.
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Tuberculosis (TB) is a major cause of disease and death
worldwide. In 2012, an estimated 8.6 million people
around the world developed active TB and 1.3 million
people died of the disease [1]. One of the challenges for
effective TB control is ensuring patients with TB
complete a full course of treatment [2].
With directly observed therapy (DOT) - a TB control
strategy recommended by the World Health Organization
(WHO) - patients are observed as they take their medicine,
with the aim to increase adherence to treatment [3]. Super-
vision of TB treatment through DOT at health clinics is
resource-intensive and can put additional pressure on* Correspondence: Cameron.wright@utas.edu.au
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unless otherwise stated.health systems, particularly in settings with a high TB bur-
den and constrained resources [4]. It can also be inconveni-
ent for patients to visit a health clinic daily for treatment
supervision, for reasons including travel and waiting times
[5]. DOT also adds direct (e.g. transport costs) and indirect
costs (e.g. in terms of time lost) to treatment [6] and these
have been shown in several cases to be higher per case suc-
cessfully treated for clinic DOT versus community-based
DOT (CB DOT) [6-8]. For these reasons, CB DOT pre-
sents an alternative for policy makers, especially when the
DOT provider is acceptable and accessible to the patient
[5]. As a 2003 WHO report on community contribution to
TB care pointed out, “Organised community groups, peer
groups, chosen members of the community, and family
members all have the potential to act as supervisors to en-
sure completion of treatment and hence cure” ([4], p. 24).This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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assessed 34 studies (randomised controlled trials and obser-
vational studies) that analysed 24 TB programmes using
CB DOT [9]. The review found that programmes that of-
fered a financial reward to supervisors in the community
tended to have higher rates of treatment completion than
those that did not. However, this result may have been due
to chance (85.7% versus 77.6% respectively, p = 0.15). The
focus of this review was on describing characteristics of CB
DOT programmes (analysed based on patient characteris-
tics, operational or organisational factors) and their impact
on the treatment outcomes of CB DOT. However, treat-
ment outcomes for CB DOT were not compared with con-
ventional clinic DOT.
Family members have been shown in some settings to be
a possible option for delivering CB DOT [10-15]. However,
Frieden and Sbarbaro have questioned the appropriateness
of routine family DOTand the extent to which these results
can be generalised [16]. From a programmatic point of
view, community health workers (CHWs) or community
volunteers (CVs) may represent a group that can be more
systematically trained, motivated and monitored than fam-
ily members.
A Cochrane review, last updated in 2007, assessed the ef-
fectiveness of DOT compared to self-administered treat-
ment (SAT) [17]. It also looked at the relative efficacy of
different types of DOT delivery. It found a small benefit
from CB DOT supervised at home (with providers includ-
ing family members, CVs and CHWs), compared to SAT,
in terms of treatment success (risk ratio (RR) 1.09, 95% CI
1.02-1.16; 1,365 participants, 3 trials [12,13,18]). There was
no benefit of clinic DOT compared to SAT (RR 0.92, 95%
CI 0.78-1.08, 444 participants, 2 trials [12,19]). There was
only one randomised controlled trial (RCT) that compared
treatment success between DOT delivered by a family
member and clinic DOT [14], and one RCT that compared
cure rate between CHW-supervised DOT and clinic DOT
[20]. Both studies showed no significant difference between
the different DOT strategies.
Given the potential value of CB DOT as a means of
treatment supervision, especially in resource-constrained
settings, a systematic review assessing the effectiveness
of CB DOT compared to conventional clinic DOT in-
cluding all available studies is indicated to inform pol-
icies on DOT delivery.
This systematic review aimed to determine the effect-
iveness of CB DOT delivered by CHWs or CVs, in terms




DOT was defined as a treatment strategy where “an
appointed agent directly monitors people swallowingtheir anti-TB drugs” [17]. CB DOT was defined as DOT
provided in the community by CHWs or CVs; clinic
DOT was defined as DOT delivered at a fixed health
clinic, usually by a government health worker.
The definitions for CHWs and CVs in this review were
based on the Global Tuberculosis Report 2013 ([1], p.
35):
CHWs were defined as “people with some formal edu-
cation who have been given training to contribute to
community-based health services, including TB preven-
tion and patient care and support. Their profile, roles
and responsibilities vary greatly among countries, and
their time is often compensated by incentives in kind or
in cash.”
CVs were defined as “community members who have
been systematically sensitized about TB prevention and
care, either through a short, specific training scheme, or
through repeated, regular contact sessions with profes-
sional health workers.”
We included studies where the role of the persons de-
livering CB DOT was consistent with the definitions
above for CHW or CV, independent of the term used in
the study. Family members providing DOT for their rela-
tives were not included in this definition of CHW or
CV.
Treatment success was defined as the sum of cured
patients and patients with completed treatment, using
WHO definitions [21]. Loss to follow-up was defined as
“a TB patient who did not start treatment or whose
treatment was interrupted for two consecutive months
or more” ([21], p. 6). In the absence of reporting of the
numbers lost to follow-up, the reported number default-
ing was used instead.
Search strategy and data extraction
The Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) statement was used to
guide the methodology and reporting of this systematic
review and meta-analysis [22]. We searched the follow-
ing literature databases: MEDLINE through OvidSP and
through PubMed (1950 to 9 July 2014), EMBASE
through OvidSP (1980 to 9 July 2014) and PreMEDLINE
(on 9 July 2014). Search terms included: ‘community net-
works’, ‘community health services’, ‘community health
nursing’, ‘health services for the aged’, ‘community care’,
‘home care services’, ‘directly observed therapy’, ‘DOT’,
‘delivery of health care’, ‘community-based participatory
research’ and/or ‘tuberculosis [drug therapy, therapy]’.
The search strategy is detailed in Additional file 1.
Two authors (CMW and LW) independently reviewed
studies for compliance with the selection criteria. Papers
that passed the screening of title and abstract underwent
full article review. The reference lists of the articles se-
lected for final inclusion were also checked along with
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dependently extracted study data including: 1) study objec-
tive(s); 2) study setting; 3) study design and population size;
4) incentives provided to supervisors; 5) inclusion and ex-
clusion criteria for different DOT strategies; 6) comparator
group(s); 7) study outcomes & results; 8) study limitations;
9) main conclusion(s) and 10) study funding source(s). Dis-
agreements in article selection and data extraction were set-
tled through discussion.
Study inclusion criteria
Studies were included if they reported TB treatment out-
comes for CB DOTcompared to clinic DOT. There was no
restriction on the type of TB (pulmonary, extra-pulmonary,
drug-sensitive or drug-resistant) or method of diagnosis
(microbiological or radiological with typical clinical presen-
tation). We included RCTs and non-randomised studies
(interventional and observational). Studies were included
independent of data analysis method (intention-to-treat or
other). CB DOT and clinic DOT had to be given for the
same time period within a study and for a minimum of the
intensive phase of treatment to be included.
Exclusion criteria
The following studies were excluded from the review:
1) Studies without a full-text version available in English.
2) Letters to the editor, notes, comments, news or
newsletter items, doctoral theses, conference
proceedings (not published in a peer-reviewed
journal) and meeting minutes.
3) Studies that did not involve CHWs or CVs
delivering CB DOT, for at least the intensive phase
of treatment. For example, studies utilising family
members only as DOT supervisors were excluded.
4) Studies in which clinic DOT, for at least the
intensive phase of treatment, was not a comparator
group.
5) Studies in which CB DOT and clinic DOT were not
directly comparable. This was either because CB
DOT and clinic DOT treatment outcomes were not
separated (e.g. in cases where family members and
CHWs were both considered as CB DOT providers
without separate results reported for each), or in
cases where CB DOT was part of a comprehensive
strategy incorporating increased TB awareness and
training, and where this was not applied to the clinic
DOT comparator.
6) Studies with a major selection bias evident in
treatment allocation to CB DOT or clinic DOT.
This included:
a) studies in which patients were allocated to CB
DOT because they were not compliant with clinic
DOT or had refused to participate in clinic DOT;b) non-randomised studies in which clinic DOT and
CB DOT were delivered to patients living in
different geographical locations and where these
locations were not matched on population size,
level of economic activity or accessibility of
health services – for example, patients from rural
locations or living far from a health centre
allocated to one type of DOT, with patients from
an urban area or living near to a health centre
allocated to the other, and
c) non-randomised studies in which patient
characteristics (e.g. socio-economic status) or
severity of TB disease influenced the allocation of
DOT type.Poor study quality for other reasons than selection bias
was not an exclusion criterion.Outcomes and analysis
Data from included studies were analysed for the CB
DOT and the clinic DOT intervention. If studies add-
itionally included patients undergoing other types of
DOT supervision (e.g. DOT provided by private physi-
cians) or SAT, we only included the patients receiving
CB DOT or clinic DOT.
The primary outcome was the proportion of patients
who were successfully treated; the secondary outcome
was the proportion of patients who were lost to follow-
up. Meta-analyses were performed for both outcomes.
Review Manager Version 5.3 (Nordic Cochrane
Centre, Copenhagen, Denmark) was used to perform the
meta-analyses. As the studies were from different coun-
tries and in different permutations of CB DOT and clinic
DOT, we expected heterogeneity beyond that explained
by random differences between patient groups in the in-
dividual studies. Thus, a random effects meta-analysis
for the data was deemed more appropriate than assum-
ing fixed variation. Confidence intervals (CIs) were set at
95% and data were presented using odds ratios (ORs)
calculated via the Mantel-Haenszel method. Heterogen-
eity was quantified using the I2 value described by
Higgins and colleagues [23]. An I2 of 0% indicates no
study heterogeneity, whilst progressively higher values
represent greater inter-study heterogeneity.Assessment of study quality and risk of bias
Studies were assessed for quality using the Grading of
Recommendations Assessment, Development and Evalu-
ation (GRADE) criteria [24]. For RCTs, risk of bias was
assessed using guidelines provided by the Cochrane Col-
laboration and those parts of the guidelines that were
relevant were also used to conduct a risk of bias assess-
ment for the included non-randomised studies [25].
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Study selection
The literature search yielded 4,428 MEDLINE, 8,919
EMBASE and zero PreMEDLINE citations. In total, 8,932
publications were identified once duplicates were removed.
Of these, 8,813 were excluded based on review of the title
and abstract, leaving 119 to undergo full text review. Of
these, seven studies fulfilled the eligibility criteria
[13,20,26-30] and one further eligible study was identified
from the reference list of one of the included studies [31].
Figure 1 shows the search strategy results in detail.
References of the directly related reviews identified
through the search strategy yielded no additional eligible
studies [9,17,32].
The studies rejected excluded under criteria five and
six are included in Additional file 2 as each of theseFigure 1 Flow diagram of study selection.studies did compare CB DOT with clinic DOT, but not
in a way permitting inclusion in this systematic review
[12,14,18,33-50].
Study characteristics
Of the eight studies included in the review, seven were
non-randomised studies [13,26-31], and one was a RCT
[20]. One study randomised patients to either DOT or
SAT, however patients in the DOT arm were allowed to
select their treatment supervisor (clinic, CV or family-
supervised DOT) [13]. This study was therefore classi-
fied as a non-randomised trial based on the part that
was relevant for this review [13]. It was also the only
study where family DOT was an option. Of the other
non-randomised studies, one was a prospective cohort
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three were retrospective cohort studies [29-31].
Four of the studies focused on urban populations
[27-30], two on rural populations [20,31] and two stud-
ies on mixed urban/rural populations [13,26]. India
was the most represented country with three studies
[29-31] and a further one study each was from South
Africa [26], Thailand [13], Zambia [27], Tanzania [20]
and Iraq [28].
The selected studies included 8,203 patients in total
with 1,957 patients receiving CB DOT and 2,719 patients
receiving clinic DOT. The remainder was either super-
vised through other means (e.g. DOT provided by a fam-
ily member), received SAT rather than DOT, or was not
assessed for treatment outcomes in the study (see
Table 1). Of 4,676 eligible patients, 3,996 patients had
outcomes of treatment success (primary outcome) or
loss to follow-up (secondary outcome). The study from
South Africa did not provide specific loss to follow-up
data for the CB DOT and clinic DOT groups, thus pa-
tients lost to follow-up in this study were not included
in the total 3,996 patients with the primary or secondary
outcome assessed in the meta-analyses [26].
Even though the type of TB or method of diagnosis
was not specified in the selection criteria, the data
extracted for all eight studies were for new, sputum
smear-positive TB patients, treated with regimens for
drug-sensitive TB. In some studies DOT was provided
for only the intensive phase (first two months of treat-
ment), and then only for the first dose each week during
the continuation phase (all with thrice weekly treatment
regimens [29-31]), or DOT was replaced by SAT during
the continuation phase (daily treatment regimens
[20,27]). In one study DOT was for daily dosing in the
intensive phase only, followed by daily attendance at the
clinic to collect drugs to be taken without supervision
for the continuation phase (for both CB DOT and clinic
DOT patients) [28]. For the other two studies DOT was
provided for the entire course of treatment; one with a
daily treatment regimen [13] and the other with a five
day per week regimen [26].
Additional file 3 contains the extracted data (with re-
sults for the primary and secondary outcome) from all
eight included studies.
Study results
The results from the included studies are summarised in
Table 1. Two studies showed increased treatment success
with CB DOT compared to clinic DOT [28,30]. Five stud-
ies, including the RCT, showed no significant difference be-
tween the two DOT strategies for treatment success
[13,20,27,29,31], and one study showed similar treatment
success for newly diagnosed patients and improvement
with CB DOT for patients that had previously undergoneTB treatment [26]. In this last study, all retreatment pa-
tients received clinic DOT in the intensive phase of treat-
ment (to receive streptomycin injections) and then their
choice of CB DOT, clinic DOT or SAT during the 6-month
continuation phase [26]. Based on our inclusion criteria,
only the newly diagnosed patients, who were treated with
different DOT strategies in the intensive phase, were in-
cluded in this review.
Outcomes of meta-analyses
The meta-analysis of all eight studies for treatment suc-
cess showed that CB DOT was superior to clinic DOT
(pooled OR of 1.54, 95% CI 1.01 – 2.36, p = 0.046, I2
84% - Figure 2).
When only including prospective studies in the meta-
analysis (Figure 3), there was markedly less heterogeneity
among studies and again a significantly higher treatment
success with CB DOT compared to clinic DOT (pooled
OR 1.31, 95% CI 1.01-1.72, p = 0.045, I2 19%).
For the secondary outcome of loss to follow-up, data
were available from seven studies. Comparing CB DOT
with clinic DOT (Figure 4), the pooled OR was 0.86,
95% CI 0.48 to 1.55, and thus not significantly different
(p = 0.62, with I2 heterogeneity 83%). This remained the
case when only prospective studies were included for
meta-analysis of loss to follow-up (OR 1.14, 95% CI
0.42-3.11, p = 0.8, I2 79%) [13,20,27,28].
Assessment of study quality and risk of bias
Based on the GRADE criteria [24], the quality of the in-
cluded studies ranged from very low [13,26-29,31] to
low [20,30]. The quality and the risk of bias assessments
are provided in Additional file 4.
Discussion
This systematic review and meta-analysis of eight studies
that compared treatment outcomes of CB DOT with
clinic DOT showed that CB DOT was associated with
higher treatment success than clinic DOT. There was
substantial inter-study heterogeneity associated with this
pooled analysis. However, the benefit from CB DOT for
treatment success compared to clinic DOT was also seen
when including only prospective studies in the meta-
analysis, with markedly less heterogeneity among stud-
ies. There was no significant difference between CB
DOT and clinic DOT for the secondary outcome of loss
to follow-up.
Strengths of our review are strict in- and exclusion cri-
teria with clear definitions for CB DOT and clinic DOT,
study selection and data extraction by independent re-
viewers and selection of the primary and secondary out-
come prior to performing the review.
Our review also has several limitations. It is possible
that we may have missed some studies despite a
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RCT (DOT versus SAT) -
for DOT arm supervisor
self-selected.
837 total in study. 415 randomised to DOT (provider
type known for 410; 1 other did not receive DOT as
allocated, 352 received DOT via family member), 422
randomised to SAT.
Treatment success:
CB DOT: 27 of 34 (79%)
Clinic DOT: 21 of 24 (88%)
58 included in meta-analysis. Loss to follow-up:
CB DOT: 5 of 34 (15%)








Prospective cohort study 769 total in study 50 transferred away from area and
not included. 598 new patients (93 of these received
SAT) and 121 retreatment patients (not included).
Treatment success:
CB DOT: 164 of 228 (72%)
Clinic DOT: 189 of 277 (68%)
505 included in meta-analysis Loss to follow-up:
18.7% reported for the study
overall but not broken down





Open cluster RCT 522 total in study and all included in
meta-analysis.
Treatment success:
CB DOT: 117 of 221 (53%)
Clinic DOT: 148 of 301 (49%)
Loss to follow-up:
CB DOT: 88 of 221 (40%).
Clinic DOT: 74 of 301 (25%).




Non-randomised trial 168 total in study and all included in
meta-analysis
Treatment success:
CB DOT: 44 of 72 (61%)
Clinic DOT: 47 of 96 (49%)
Loss to follow-up:
CB DOT: 6 of 72 (8%)




Iraq, urban Non-randomised trial
(sequential allocation to one
treatment arm or the other)
172 total in study and all included in
meta-analysis
Treatment success:
CB DOT: 72 of 86 (84%)
Clinic DOT: 59 of 86 (69%)
Loss to follow-up:
CB DOT: 10 of 86 (12%)
Clinic DOT: 9 of 86 (10%)
Nirupa et al.
2005 [31]
India, rural Retrospective cohort study 3019 total in study Treatment success:
2661 (88%) could be contacted for the study.
Treatment results for only new sputum positive TB
patients, N = 1131. 28 patients received SAT.
Outreach workers (N = 238) excluded as neither CB
DOT nor clinic DOT.
CB DOT: 526 of 666 (79%)
Clinic DOT: 147 of 199 (74%)
865 included in meta-analysis Loss to follow-up:
CB DOT 92 of 666 (14%)





Retrospective cohort study 617 total in study and all included in meta-analysis Treatment success:
CB DOT: 110 of 141 (78%)
Clinic DOT: 367 of 476 (77%)
Loss to follow-up:
CB DOT: 21 of 141 (15%)
Clinic DOT: 69 of 476 (14%)
Wright et al. BMC Infectious Diseases  (2015) 15:210 Page 6 of 11





Retrospective cohort study 2099 total in study Treatment success:
Treatment cards of 1864 (89%) available for
evaluation. Patients supervised by physicians (N = 95)
removed from CB DOT results.
CB DOT: 475 of 509 (93%)
Clinic DOT: 951 of 1260 (75%)
1769 included in meta-analysis Loss to follow-up:
CB DOT: 13 of 509 (3%)
Clinic DOT: 88 of 1260 (7%)
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limited by substantial inter-study heterogeneity. However,
there was significantly less heterogeneity among prospect-
ive studies only, and a meta-analysis of this subgroup con-
firmed a higher treatment success rate with CB DOT
compared to clinic DOT. Furthermore, the quality of the
reviewed studies was generally low (see quality assessment
in Additional file 4). As in all systematic reviews, reporting
bias has to be considered. However, as there are less than
ten studies in this meta-analysis, funnel plot asymmetry
tests are not appropriate as “the power of the tests is too
low to distinguish chance from real asymmetry” ([25], sec-
tion 10.4.3.1). Following from these limitations, the result
of the meta-analysis for treatment success needs to be
interpreted with caution.
Studies in which CB DOT and clinic DOT programmes
could not be directly compared (criterion 5), or where an
allocation bias was evident (criterion 6), were excluded
from this review (these are listed in Additional file 2).
However, the included studies were still subject to risk of
bias (see Additional file 4 for these assessments). Some
points warrant further examination to ensure that the
higher treatment success for CB DOT found in our meta-
analysis was truly due to type of DOT supervision rather
than due to systematic differences between the clinic
DOT and CB DOT groups.
In the RCT from Tanzania, the largest treatment centre in
the study was randomised to clinic DOT [20]. According toFigure 2 Forest plot of treatment success for CB DOT versus clinic DOT. Th
included in the meta-analysis.the study authors, this centre was likely to have had a higher
proportion of patients with relatively more severe TB and
thus with a lower likelihood of treatment success, compared
to other study areas. This was a weakness of the cluster ran-
domisation design and the authors note that their study
“may have resulted in an overestimate of the benefits of
CBDOT”. Other potential sources of bias in this RCT were
unclear method of randomisation, inadequate (or unclear)
allocation concealment and blinding of assessors, and a 31%
loss to follow-up. This overall risk of bias means that this
RCT constitutes relatively low quality evidence according to
the GRADE criteria [24]. The study that allowed for super-
visor self-selection for those patients randomly allocated to
DOT (as opposed to SAT) was obviously prone to a sub-
stantial risk of selection bias [13]. Another important source
of potential allocation bias was involvement of health
workers in the decision who would receive CB DOT or
clinic DOT [26,30,31]. None of these studies outlined any
criteria to guide this allocation. While we cannot exclude
that some of the potential selection biases discussed above
impacted on overall treatment success for CB DOT and
clinic DOT, none of the included studies had an apparent
systematic selection bias for including patients in either the
CB DOT or clinic DOT group, thus making it likely that the
type of DOT was indeed the major cause of the difference
in treatment outcomes.
While patient self-selection of DOT supervisor and/or
consultation with a health worker adds potential studye size of the symbols is proportional to the number of patients
Figure 3 Forest plot of treatment success for CB DOT versus clinic DOT, prospective studies only. The size of the symbols is proportional to the
number of patients included in the meta-analysis.
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factor in treatment success. The authors of the study from
Thailand, in which DOT led to higher cure and treatment
completion rates than SAT, noted that: “Giving patients a
variety of supervision options and focusing on their con-
venience may have contributed to the comparatively
favourable results in this study” [13]. CB DOT removes
the need to attend the clinic daily for TB treatment and
this may help to address some of the barriers– which in-
clude time away from work–faced by patients receiving
DOT [5]. Non-randomised studies where CB DOT and
clinic DOT were assigned to patients from ‘unmatched’
geographical locations (e.g. rural for CB DOT versus
urban for clinic DOT) were excluded from the review
[12,49,50]. While this exclusion was made to increase the
likelihood that differences in treatment outcomes were at-
tributable to the DOT type rather than other factors, it
may be that patients living greater distances from health
facilities will benefit most from CB DOT being made
available as a treatment option. Indeed, the results for CB
DOT in terms of cure were at least equivalent to clinic
DOT in each of these three studies [12,49,50]. While it
may be beneficial in many cases, some risks, such as
stigma, can still be associated with CB DOT. In the studyFigure 4 Forest plot of loss to follow-up for CB DOT versus clinic DOT. The
in the meta-analysis.from Zambia, many of the patients not previously regis-
tered with the ‘home care programme’ which delivered
CB DOT, opted for clinic DOT instead (see risk of bias as-
sessment in Additional file 4 for more details) [27]. This
was due to the perception that community members
would assume that they had HIV as well as TB if they saw
community observers visiting them [27].
A limitation of the meta-analysis was that it did not
allow to definitely establish the reason for increased treat-
ment success among patients receiving CB DOT. In-
creased treatment success could be the consequence of
lower rates of loss to follow-up (the secondary outcome
for our study), lower rates of treatment failure or lower
rates of death. While it is generally justified to assume that
a significant proportion of treatment failures is caused by
lack of adherence to TB treatment, undiagnosed drug-
resistance of M. tuberculosis can substantially contribute
to treatment failures in settings with relatively high pro-
portions of drug-resistance in the community and lack of
routine testing for drug-susceptibility [51]. However, it is
unlikely that patients with epidemiological and medical
risk factors for drug-resistant (DR) TB (such as retreat-
ment cases, all data for meta-analyses were for newly diag-
nosed patients) were over-represented in the clinic DOTsize of the symbols is proportional to the number of patients included
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This is again due to the exclusion of studies with apparent
systematic selection bias for patient allocation to CB DOT
or clinic DOT.
The forest plot for the secondary outcome - loss to follow
up (Figure 4) - showed a wide spread of results. Brief dis-
cussion of the study showing higher loss to follow-up for
CB DOT relative to clinic DOT in our meta-analysis is pro-
vided in Additional file 3 [20]. While numbers lost to
follow-up can be seen as being patients who ‘defaulted’ on
treatment, it is also possible that in some cases this out-
come was a reflection of the quality of the research study as
well as of outcomes of the DOT programme. The authors
of the RCT report that the pragmatic nature of the trial
“was largely the reason for a higher than-desirable number
of missing outcomes” [20], reflecting the difficulties con-
ducting this kind of research. In most of the included stud-
ies a specific definition for the loss to follow-up (or default)
outcome was not provided [13,20,27,29,31]. Thus there is a
risk that in some cases the patients assigned as being lost to
follow-up were actually ‘not evaluated’ (e.g. ‘transferred
out’) according to WHO treatment outcome definitions
[21]. Even so, results for ‘transferred out’ were reported for
all but one of the studies where the loss to follow-up defin-
ition was not specifically defined [31] meaning that this
should have had a limited impact on the secondary out-
come meta-analysis, and no impact on the treatment suc-
cess meta-analysis result.
A Cochrane review assessed TB treatment success of
DOT compared to SAT and if this was affected by the
type of supervision provided in the DOT group [17].
The authors only identified one RCT that compared CB
DOT and clinic DOT. This RCT- that we have also in-
cluded in our meta-analysis- did not show any signifi-
cant difference between CB DOT and clinic DOT in
terms of cure [20].
A systematic review and meta-analysis published in
2009 examined the impact of different designs of CB
DOT programmes on treatment outcomes [9]. Compo-
nents of CB DOT programmes were categorised into pa-
tient, operational, and organisational characteristics.
Studies in which the community-based supervisor was a
health professional, family member, CHW or CV were
included; though supervision needed to be at a place
other than a health facility or ‘TB club’. It showed a pos-
sible (albeit plausibly due to chance) benefit from offer-
ing a financial reward to DOT supervisors (85.7% versus
77.6% for treatment completion, p = 0.15). The effective-
ness in terms of treatment outcomes of CB DOT com-
pared to clinic DOT was not examined in that review.
In the studies included in our systematic review, finan-
cial incentives to CHWs or CVs were not offered for
providing DOT, or it was not stated whether these were
provided or not (see Additional file 3 for further detailsabout individual studies). However, using incentives as a
motivator for DOT supervisors appears to be a common
practice. This could be in the form of a regular salary,
for example in the case of health extension workers in
southern Ethiopia [35] or treatment supporters in South
Africa [52]. Other forms of remuneration for treatment
supervisors, sometimes involving patient co-payments,
are also described in the literature [53].
Additional qualitative and quantitative aspects of com-
munity involvement in TB care have also been discussed
in a review article and a WHO report [4,32]. These fo-
cused on the design of CB DOT programmes and their
place in a wider policy context. Issues of accountability
of CHWs or CVs, the need for training and variation in
the quality of community-based supervision were raised
by individual studies included in our review and these
are important to consider during CB DOT programme
design and monitoring.
While we acknowledge that the result of this system-
atic review has to be interpreted with caution, given the
limitations outlined above, the result of higher treatment
success is encouraging given the potential role of CB
DOT as a means of treatment supervision, especially in
resource-constrained settings.
CB DOT may also provide a means by which DR TB
(multidrug-resistant (MDR)-TB or extensively drug-
resistant (XDR) TB) can be supervised effectively, al-
though all of the included studies in this review reported
outcomes for patients treated with regimens for drug-
sensitive TB. A recently published systematic review and
meta-analysis – published prior to but indexed after our
database search - has reported treatment outcomes from
community-based DR TB programmes, though it did
not compare the treatment success of CB DOT with
conventional clinic DOT and none of the included stud-
ies were eligible for our review [54]. The review showed
a pooled treatment success of 65% for 1,288 patients
across ten studies with community-based interventions
(including DOT by family members, neighbours, co-
workers, local health care workers and former patients).
This is comparable to outcomes seen in earlier meta-
analyses of DR-TB treatment success [55-57].
Conclusions
Our meta-analysis showed a benefit from CB DOT com-
pared to clinic DOT for treatment success, but no over-
all difference between the two DOT strategies for loss to
follow-up. This result in favour of CB DOT for treat-
ment success was also seen when only analysing data
from prospective studies. The lack of high quality RCTs
limits the strength of this result. However, based on the
review result, we suggest that CB DOT can be consid-
ered as an alternative to clinic DOT for the treatment of
TB patients, delivering at least equivalent treatment
Wright et al. BMC Infectious Diseases  (2015) 15:210 Page 10 of 11success. Future studies should also assess the cost-
effectiveness of CB DOT compared to clinic DOT, which is
essential for health policy makers, especially in resource-
constrained settings.Additional files
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